IP Library › Patent Application 17676654
Patent Application
App. No. 17/676,654

TREATING MYELOMAS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/676,654
Abstract

This document provides methods and materials related to treating myelomas. For example, methods and materials re-lating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.

Claims (25)

1 . A method for treating a mammal having myeloma, said method comprising administering to said mammal a composition comprising nanoparticles containing albumin and paclitaxel complexed with an anti-CD38 polypeptide antibody, wherein an average diameter of the nanoparticles is less than 1 μm.

2 - 3 . (canceled)

4 . The method of claim 1 , wherein the anti-CD38 polypeptide antibody is Daratumumab, MOR202, SAR650984, or any combination thereof.

5 . The method of claim 1 , wherein said composition comprises an alkylating agent complexed with said nanoparticles.

6 . The method of claim 5 , wherein said alkylating agent is a platinum compound.

7 . The method of claim 6 , wherein said platinum compound is carboplatin.

8 . The method of claim 1 , wherein said anti-CD38 polypeptide antibody is a humanized antibody.

9 . The method of claim 1 , wherein said anti-CD38 polypeptide antibody is a chimeric antibody.

10 . The method of claim 1 , wherein said composition is administered by injection.

11 . The method of claim 1 , wherein administering the composition increases a length of progression-free survival in the mammal.

12 - 15 . (canceled)

16 . The method of claim 1 , wherein administering the composition increases a time to progression.

17 - 25 . (canceled)

26 . The method of claim 1 , wherein said composition comprises an anti-inflammatory agent.

27 - 33 . (canceled)

34 . The method of claim 1 , wherein said administration of said composition increases a median time to progression for a population of mammals with said myeloma to at least 150 days.

35 . The method of claim 1 , wherein said administration of said composition increases a median time to progression for a population of mammals with said myeloma is at least 165 days.

36 . The method of claim 17 , wherein said administration of said composition increases a median time to progression for a population of mammals with said myeloma is at least 170 days.

37 . The method of claim 1 , wherein the average diameter of the nanoparticles is from 0.1 μm to 0.3 μm.

38 . The method of claim 1 , wherein the average diameter of the nanoparticles is from 0.15 μm to 0.3 μm.

39 . The method of claim 1 , wherein the average diameter of the nanoparticles is from 0.2 μm to 0.5 μm.

40 . The method of claim 1 , wherein the average diameter of the nanoparticles is from 0.3 μm to 0.5 μm.

41 . The method of claim 1 , wherein the average diameter of the nanoparticles is from 0.2 μm to 0.8 μm.

42 . The method of claim 1 , wherein the average diameter of the nanoparticles is from 0.2 μm to 0.7 μm.

43 - 72 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2022
From: MARKOVIC, SVETOMIR N.; NEVALA, WENDY K.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 059238/0564 →